Molecular genetics of successful smoking cessation: convergent genome-wide association study results.
BACKGROUND
Smoking remains a major public health problem. Twin studies indicate that the ability to quit smoking is substantially heritable, with genetics that overlap modestly with the genetics of vulnerability to dependence on addictive substances.


OBJECTIVE
To identify replicated genes that facilitate smokers' abilities to achieve and sustain abstinence from smoking (herein after referred to as quit-success genes) found in more than 2 genome-wide association (GWA) studies of successful vs unsuccessful abstainers, and, secondarily, to nominate genes for selective involvement in smoking cessation success with bupropion hydrochloride vs nicotine replacement therapy (NRT).


METHODS
The GWA results in subjects from 3 centers, with secondary analyses of NRT vs bupropion responders.


METHODS
Outpatient smoking cessation trial participants from 3 centers.


METHODS
European American smokers who successfully vs unsuccessfully abstain from smoking with biochemical confirmation in a smoking cessation trial using NRT, bupropion, or placebo (N = 550).


METHODS
Quit-success genes, reproducibly identified by clustered nominally positive single-nucleotide polymorphisms (SNPs) in more than 2 independent samples with significant P values based on Monte Carlo simulation trials. The NRT-selective genes were nominated by clustered SNPs that display much larger t values for NRT vs placebo comparisons. The bupropion-selective genes were nominated by bupropion-selective results.


RESULTS
Variants in quit-success genes are likely to alter cell adhesion, enzymatic, transcriptional, structural, and DNA, RNA, and/or protein-handling functions. Quit-success genes are identified by clustered nominally positive SNPs from more than 2 samples and are unlikely to represent chance observations (Monte Carlo P< .0003). These genes display modest overlap with genes identified in GWA studies of dependence on addictive substances and memory.


CONCLUSIONS
These results support polygenic genetics for success in abstaining from smoking, overlap with genetics of substance dependence and memory, and nominate gene variants for selective influences on therapeutic responses to bupropion vs NRT. Molecular genetics should help match the types and/or intensity of antismoking treatments with the smokers most likely to benefit from them.
Uhl
George R
GR
Molecular Neurobiology Research Branch, National Institutes of Health-Intramural Research Program, National Institute on Drug Abuse, 333 Cassell Dr, Ste 3510, Baltimore, MD 21224, USA. guhl@intra.nida.nih.gov
Liu
Qing-Rong
QR
Drgon
Tomas
T
Johnson
Catherine
C
Walther
Donna
D
Rose
Jed E
JE
David
Sean P
SP
Niaura
Ray
R
Lerman
Caryn
C
D000328:Adult; D000483:Alleles; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage; D016642:Bupropion / Q000008:administration & dosage; D002874:Chromosome Mapping; D018849:Controlled Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005819:Genetic Markers / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D014644:Genetic Variation / Q000235:genetics*; D016678:Genome; D006801:Humans; D008297:Male; D009010:Monte Carlo Method; D009538:Nicotine / Q000008:administration & dosage; D018722:Nicotinic Agonists / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D012907:Smoking / Q000235:genetics*; D016540:Smoking Cessation; D014029:Tobacco Use Disorder / Q000235:genetics* / Q000534:rehabilitation; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D005819:Genetic Markers; D018722:Nicotinic Agonists; D016642:Bupropion; D009538:Nicotine